Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × infigratinib × Genitourinary × Clear all

Phase

Phase 1 2 Phase NA 1 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1 Gastrointestinal 1

Conditions

Upper Tract Urothelial Carcinomas 1

Interventions

Docetaxel 68 Radiotherapy 65 Prednisone 60 Leuprolide 43 Goserelin 43 Gemcitabine 42 Cisplatin 42 bicalutamide 41 enzalutamide 37 Androgen Antagonists 31 pembrolizumab 27 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 27 Mitomycin 27 Carboplatin 26 Abiraterone Acetate 26 Magnetic Resonance Spectroscopy 25 Flutamide 22 apalutamide 21 Triptorelin Pamoate 21 Sunitinib 20 Nivolumab 20 Radiation 19 Doxorubicin 17 Paclitaxel 15 Gonadotropin-Releasing Hormone 15 darolutamide 14 cabozantinib 14 Zoledronic Acid 14 cabazitaxel 13 atezolizumab 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04197986 2024-03-13

PROOF302

QED Therapeutics, a BridgeBio company

Phase 3 Terminated

39 enrolled 31 charts

Upper Tract Urothelial Carcinomas

Data powered by HemOnc (CC BY 4.0) Colophon ⚡